RU2017120330A - Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы - Google Patents
Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы Download PDFInfo
- Publication number
- RU2017120330A RU2017120330A RU2017120330A RU2017120330A RU2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A RU 2017120330 A RU2017120330 A RU 2017120330A
- Authority
- RU
- Russia
- Prior art keywords
- breast cancer
- subject
- basal
- classifier
- assessment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 62
- 206010006187 Breast cancer Diseases 0.000 title claims 38
- 208000026310 Breast neoplasm Diseases 0.000 title claims 38
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 claims 24
- 108010080146 androgen receptors Proteins 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 24
- 210000004027 cell Anatomy 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 14
- 229960004671 enzalutamide Drugs 0.000 claims 14
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 229930012538 Paclitaxel Natural products 0.000 claims 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 6
- 229960001592 paclitaxel Drugs 0.000 claims 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 6
- -1 galerona Chemical compound 0.000 claims 5
- 229940127084 other anti-cancer agent Drugs 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- OZPFIJIOIVJZMN-SFHVURJKSA-N 6-[(7s)-7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl]-n-methylnaphthalene-2-carboxamide Chemical compound C1=CC2=CC(C(=O)NC)=CC=C2C=C1[C@]1(O)C2=CN=CN2CC1 OZPFIJIOIVJZMN-SFHVURJKSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 4
- 239000010839 body fluid Substances 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 3
- 239000003098 androgen Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 238000011156 evaluation Methods 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 claims 2
- 108010069236 Goserelin Proteins 0.000 claims 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 108010000817 Leuprolide Proteins 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 229960002184 abarelix Drugs 0.000 claims 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims 2
- 108010023617 abarelix Proteins 0.000 claims 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 2
- 229960004103 abiraterone acetate Drugs 0.000 claims 2
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960000997 bicalutamide Drugs 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960000978 cyproterone acetate Drugs 0.000 claims 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims 2
- 229960001251 denosumab Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960003649 eribulin Drugs 0.000 claims 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 2
- 229960004039 finasteride Drugs 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 2
- 229960002074 flutamide Drugs 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 229960002913 goserelin Drugs 0.000 claims 2
- 229940015872 ibandronate Drugs 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960002014 ixabepilone Drugs 0.000 claims 2
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 2
- 229960004125 ketoconazole Drugs 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 2
- 229960004338 leuprorelin Drugs 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 229960004296 megestrol acetate Drugs 0.000 claims 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 2
- 229960002653 nilutamide Drugs 0.000 claims 2
- 210000002445 nipple Anatomy 0.000 claims 2
- 229950004023 orteronel Drugs 0.000 claims 2
- 229940046231 pamidronate Drugs 0.000 claims 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229960004622 raloxifene Drugs 0.000 claims 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 2
- 229940089617 risedronate Drugs 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 2
- 229960005026 toremifene Drugs 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 229960004276 zoledronic acid Drugs 0.000 claims 2
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 238000004445 quantitative analysis Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462091195P | 2014-12-12 | 2014-12-12 | |
| US62/091,195 | 2014-12-12 | ||
| US201562142504P | 2015-04-03 | 2015-04-03 | |
| US62/142,504 | 2015-04-03 | ||
| US201562167110P | 2015-05-27 | 2015-05-27 | |
| US62/167,110 | 2015-05-27 | ||
| PCT/US2015/064500 WO2016094408A1 (en) | 2014-12-12 | 2015-12-08 | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017120330A true RU2017120330A (ru) | 2019-01-14 |
| RU2017120330A3 RU2017120330A3 (https=) | 2019-07-24 |
Family
ID=55273509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017120330A RU2017120330A (ru) | 2014-12-12 | 2015-12-08 | Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10196693B2 (https=) |
| EP (2) | EP3604556A1 (https=) |
| JP (1) | JP6735277B2 (https=) |
| KR (1) | KR20170095306A (https=) |
| CN (1) | CN107109488A (https=) |
| AU (1) | AU2015360767A1 (https=) |
| BR (1) | BR112017012142A2 (https=) |
| CA (1) | CA2970469A1 (https=) |
| ES (1) | ES2748005T3 (https=) |
| IL (1) | IL252587A0 (https=) |
| MX (1) | MX2017007707A (https=) |
| RU (1) | RU2017120330A (https=) |
| SG (1) | SG11201704425TA (https=) |
| WO (1) | WO2016094408A1 (https=) |
| ZA (1) | ZA201703904B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101923250B1 (ko) | 2011-07-29 | 2018-11-28 | 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 | 유방암의 치료 |
| US20140243211A1 (en) | 2013-02-28 | 2014-08-28 | Indiana University Research & Technology Corporation | Blood biomarkers for suicidality |
| SG11201704425TA (en) | 2014-12-12 | 2017-06-29 | Medivation Prostate Therapeutics Inc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
| WO2016201299A1 (en) | 2015-06-12 | 2016-12-15 | Indiana University Research & Technology Corporation | Predicting suicidality using a combined genomic and clinical risk assessment |
| KR101966493B1 (ko) * | 2016-06-27 | 2019-04-05 | 국립암센터 | 삼중음성유방암 예후 예측용 바이오마커 |
| KR101896558B1 (ko) * | 2016-11-21 | 2018-09-07 | 주식회사 젠큐릭스 | 유방암 환자의 예후 예측 방법 |
| JPWO2018198927A1 (ja) * | 2017-04-26 | 2019-11-07 | 日本電信電話株式会社 | Ｎ×ｎ光スイッチ |
| CA3105451A1 (en) | 2017-05-12 | 2018-11-15 | Indiana University Research And Technology Corporation | Precision medicine for treating and preventing suicidality |
| RU2648523C1 (ru) * | 2017-05-22 | 2018-03-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию |
| CA3105389C (en) * | 2018-05-14 | 2025-05-20 | Hinova Pharmaceuticals Inc. | A formulation of hc-1119 as well as the production method and the use thereof |
| WO2020001473A1 (zh) * | 2018-06-28 | 2020-01-02 | 复旦大学 | 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途 |
| CN109735625A (zh) * | 2019-03-18 | 2019-05-10 | 马榕 | 乳头溢液在检测肿瘤相关基因中的应用 |
| CN114334000B (zh) * | 2021-12-28 | 2025-07-25 | 上海中医药大学 | 基于转录组图谱的组合药物生成方法、系统及存储介质 |
| US20260043086A1 (en) * | 2022-08-06 | 2026-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarker in avastin in colon cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| EP1027456B1 (en) | 1997-10-31 | 2005-03-16 | Affymetrix, Inc. (a Delaware Corporation) | Expression profiles in adult and fetal organs |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6937713B1 (en) | 1999-12-30 | 2005-08-30 | At&T Corp. | IP call forward profile |
| US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20070192880A1 (en) | 2003-10-03 | 2007-08-16 | University Of Rochester | Horming response element binding transregulators |
| US20070059720A9 (en) | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| JP4644737B2 (ja) | 2005-05-13 | 2011-03-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジアリールヒダントイン化合物 |
| CA2630974A1 (en) | 2005-11-23 | 2007-05-31 | University Of Utah Research Foundation | Methods and compositions involving intrinsic genes |
| LT2656842T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| KR101456722B1 (ko) | 2006-03-29 | 2014-10-31 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴티오히단토인 화합물 |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| DK2297359T3 (en) | 2008-05-30 | 2014-02-24 | Univ Utah Res Found | Gene expression profiles to predict the outcome of breast cancer |
| NZ594741A (en) | 2009-02-24 | 2014-03-28 | Medivation Prostate Therapeutics Inc | Specific diarylhydantoin and diarylthiohydantoin compounds |
| EP2416657A4 (en) | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| EP2425015B1 (en) | 2009-04-29 | 2018-01-10 | Ralph Wirtz | A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels |
| WO2011022316A1 (en) | 2009-08-20 | 2011-02-24 | The Regents Of The University Of Colorado, A Body Corporate | Mirnas dysregulated in triple-negative breast cancer |
| JP2013504064A (ja) | 2009-09-03 | 2013-02-04 | ザ スクリプス リサーチ インスティチュート | 循環腫瘍細胞を分類する方法 |
| WO2011044327A1 (en) | 2009-10-07 | 2011-04-14 | Medivation Prostate Therapeutics, Inc. | Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds |
| US8781912B2 (en) | 2011-03-15 | 2014-07-15 | Opera Solutions, Llc | Computer-based method and computer program product for setting floor prices for items sold at auction |
| AU2012229123B2 (en) * | 2011-03-15 | 2017-02-02 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with anthracycline therapy |
| KR101923250B1 (ko) | 2011-07-29 | 2018-11-28 | 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 | 유방암의 치료 |
| AU2012345789B2 (en) | 2011-11-30 | 2018-02-15 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with taxane therapy |
| US10175240B2 (en) | 2012-08-23 | 2019-01-08 | The Regents Of The University Of Colorado, A Body Corporate | Method for determining breast cancer treatment |
| US9175291B2 (en) * | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| US20140154681A1 (en) | 2012-11-12 | 2014-06-05 | Nanostring Technologies, Inc. | Methods to Predict Breast Cancer Outcome |
| US10679730B2 (en) * | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
| SG11201704425TA (en) | 2014-12-12 | 2017-06-29 | Medivation Prostate Therapeutics Inc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
-
2015
- 2015-12-08 SG SG11201704425TA patent/SG11201704425TA/en unknown
- 2015-12-08 US US14/962,864 patent/US10196693B2/en active Active
- 2015-12-08 RU RU2017120330A patent/RU2017120330A/ru not_active Application Discontinuation
- 2015-12-08 BR BR112017012142A patent/BR112017012142A2/pt not_active IP Right Cessation
- 2015-12-08 EP EP19192143.6A patent/EP3604556A1/en not_active Withdrawn
- 2015-12-08 MX MX2017007707A patent/MX2017007707A/es unknown
- 2015-12-08 KR KR1020177019159A patent/KR20170095306A/ko not_active Withdrawn
- 2015-12-08 AU AU2015360767A patent/AU2015360767A1/en not_active Abandoned
- 2015-12-08 JP JP2017531209A patent/JP6735277B2/ja not_active Expired - Fee Related
- 2015-12-08 ES ES15831013T patent/ES2748005T3/es active Active
- 2015-12-08 WO PCT/US2015/064500 patent/WO2016094408A1/en not_active Ceased
- 2015-12-08 CN CN201580068041.7A patent/CN107109488A/zh active Pending
- 2015-12-08 CA CA2970469A patent/CA2970469A1/en active Pending
- 2015-12-08 EP EP15831013.6A patent/EP3230471B1/en not_active Not-in-force
-
2017
- 2017-05-30 IL IL252587A patent/IL252587A0/en unknown
- 2017-06-07 ZA ZA2017/03904A patent/ZA201703904B/en unknown
-
2018
- 2018-12-10 US US16/215,340 patent/US11186876B2/en active Active
-
2021
- 2021-11-10 US US17/523,235 patent/US11952634B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11952634B2 (en) | 2024-04-09 |
| MX2017007707A (es) | 2018-03-06 |
| US20220056541A1 (en) | 2022-02-24 |
| EP3230471A1 (en) | 2017-10-18 |
| JP2018504892A (ja) | 2018-02-22 |
| WO2016094408A1 (en) | 2016-06-16 |
| US20160168646A1 (en) | 2016-06-16 |
| CA2970469A1 (en) | 2016-06-16 |
| JP6735277B2 (ja) | 2020-08-05 |
| US20190169697A1 (en) | 2019-06-06 |
| IL252587A0 (en) | 2017-07-31 |
| SG11201704425TA (en) | 2017-06-29 |
| KR20170095306A (ko) | 2017-08-22 |
| ES2748005T3 (es) | 2020-03-12 |
| US11186876B2 (en) | 2021-11-30 |
| ZA201703904B (en) | 2019-12-18 |
| EP3604556A1 (en) | 2020-02-05 |
| BR112017012142A2 (pt) | 2018-01-02 |
| AU2015360767A1 (en) | 2017-06-08 |
| RU2017120330A3 (https=) | 2019-07-24 |
| CN107109488A (zh) | 2017-08-29 |
| EP3230471B1 (en) | 2019-08-28 |
| US10196693B2 (en) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017120330A (ru) | Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы | |
| JP2018504892A5 (https=) | ||
| US11730736B2 (en) | Anticancer agents | |
| IL228449A (en) | Signs of Efficacy of Breast Cancer Methods with Anthracycline Therapy | |
| EP3454844A1 (en) | Combination therapies of hdac inhibitors pd-1 inhibitors | |
| WO2017197140A1 (en) | Combination therapies of hdac inhibitors and pd-l1 inhibitors | |
| HRP20212033T1 (hr) | Anti-lag-3 antitijela za liječenje hematoloških maligniteta | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| JP2017535534A (ja) | がんを治療するための単独または併用療法におけるｃｃｒ５拮抗剤の使用 | |
| CN108779111B (zh) | 结合脱氧胞苷激酶的化合物 | |
| MX2012012075A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con ligandos erbb/erbb. | |
| RU2013137380A (ru) | Комбинация сиросингопина и митохондриальных ингибиторов для лечения рака и для иммуносупрессии | |
| EP3720560A1 (en) | Methods of treating cancer with plk4 inhibitors | |
| RU2016148441A (ru) | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом | |
| Shao et al. | Recent Progress on primary central nervous system lymphoma—from Bench to Bedside | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| RU2488173C1 (ru) | Способ создания биологической модели умеренного торможения роста опухоли и метастазов карциномы легких льюис с продолжительной циклофосфаниндуцированной лейкопенией у мышей | |
| RU2017112998A (ru) | Способ лечения солидного рака и/или его метастазов, предназначенные для этого медикаменты и способ прогнозирования клинического исхода лечения солидного рака и/или его метастазов | |
| RU2532342C1 (ru) | Способ прогнозирования рецидива рака вульвы | |
| RU2372081C1 (ru) | Композиция, обладающая иммуностимулирующей и антиоксидантной активностью | |
| RU2015129366A (ru) | Способы и композиции, относящиеся к лечению злокачественной опухоли | |
| Nguyen et al. | Occult colon cancer with initial cutaneous metastatic manifestation: PET/CT detection | |
| RU2408082C1 (ru) | Способ оценки сочетанного действия цитостатика и внешнего гамма-облучения в эксперименте | |
| RU2488890C1 (ru) | Способ моделирования хронической цитостатической миелосупрессии | |
| Jin et al. | OS12. 4. A AI-BASED HISTOPATHOLOGICAL CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMOURS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20191106 |